1. known or suspected allergy to rapa 2. high pro-calcitonin 3. sars-cov2 documented by negative rt-pcr nasopharyngeal swab 4. treatment with contraindicated concomitant medications: currently receiving immunosuppressants, including steroids, prior to enrollment, or with immunomodulators or immunosuppressant drugs, including but not limited to inter leukin (il)-6 inhibitors, tumor necrosis factor (tnf) inhibitors, anti-il-1 agents and janus kinase (jak) inhibitors within 5 half-lives or 30 days (whichever is longer) prior to randomization. 5. currently receiving immunosuppressants, including steroids, prior to enrollment 6. serious underlying disease including but not limited to cardiac, pulmonary, renal, hepatic (bilirubin \>1.5x upper normal limit (uln) or aspartate aminotransferase (ast)\>uln but bilirubin ≤ uln), endocrine (diabetes) or psychiatric disorders judged to be at risk in participating by the inpatient attending physician or team 7. suspected or confirmed history of alcohol or substance abuse disorder 8. having participated in other drug trials in the past month 9. deemed otherwise unsuitable for the study by researchers 10. clinically judged to not require hospital admission

1. known or suspected allergy to rapa 2. high pro-calcitonin 3. sars-cov2 documented by negative rt-pcr nasopharyngeal swab 4. treatment with contraindicated concomitant medications: currently receiving immunosuppressants, including steroids, prior to enrollment, or with immunomodulators or immunosuppressant drugs, including but not limited to inter leukin (il)-6 inhibitors, tumor necrosis factor (tnf) inhibitors, anti-il-1 agents and janus kinase (jak) inhibitors within 5 half-lives or 30 days (whichever is longer) prior to randomization. 5. currently receiving immunosuppressants, including steroids, prior to enrollment 6. serious underlying disease including but not limited to cardiac, pulmonary, renal, hepatic (bilirubin \>1.5x upper normal limit (uln) or aspartate aminotransferase (ast)\>uln but bilirubin ≤ uln), endocrine (diabetes) or psychiatric disorders judged to be at risk in participating by the inpatient attending physician or team 7. suspected or confirmed history of alcohol or substance abuse disorder 8. having participated in other drug trials in the past month 9. deemed otherwise unsuitable for the study by researchers 10. clinically judged to not require hospital admission

known or suspected allergy to rapa high pro-calcitonin sars-cov2 documented by negative rt-pcr nasopharyngeal swab treatment with contraindicated concomitant medications: currently receiving immunosuppressants, including steroids, prior to enrollment, or with immunomodulators or immunosuppressant drugs, including but not limited to inter leukin (il)-6 inhibitors, tumor necrosis factor (tnf) inhibitors, anti-il-1 agents and janus kinase (jak) inhibitors within 5 half-lives or 30 days (whichever is longer) prior to randomization. currently receiving immunosuppressants, including steroids, prior to enrollment serious underlying disease including but not limited to cardiac, pulmonary, renal, hepatic (bilirubin >1.5x upper normal limit (uln) or aspartate aminotransferase (ast)>uln but bilirubin ≤ uln), endocrine (diabetes) or psychiatric disorders judged to be at risk in participating by the inpatient attending physician or team suspected or confirmed history of alcohol or substance abuse disorder having participated in other drug trials in the past month deemed otherwise unsuitable for the study by researchers clinically judged to not require hospital admission

known or suspected allergy to rapa high pro-calcitonin sars-cov2 documented by negative rt-pcr nasopharyngeal swab treatment with contraindicated concomitant medications: currently receiving immunosuppressants, including steroids, prior to enrollment, or with immunomodulators or immunosuppressant drugs, including but not limited to inter leukin (il)-6 inhibitors, tumor necrosis factor (tnf) inhibitors, anti-il-1 agents and janus kinase (jak) inhibitors within 5 half-lives or 30 days (whichever is longer) prior to randomization. currently receiving immunosuppressants, including steroids, prior to enrollment serious underlying disease including but not limited to cardiac, pulmonary, renal, hepatic (bilirubin >1.5x upper normal limit (uln) or aspartate aminotransferase (ast)>uln but bilirubin ≤ uln), endocrine (diabetes) or psychiatric disorders judged to be at risk in participating by the inpatient attending physician or team suspected or confirmed history of alcohol or substance abuse disorder having participated in other drug trials in the past month deemed otherwise unsuitable for the study by researchers clinically judged to not require hospital admission

1. known or suspected allergy to rapa 2. high pro-calcitonin 3. sars-cov2 documented by negative rt-pcr nasopharyngeal swab 4. treatment with contraindicated concomitant medications: currently receiving immunosuppressants, including steroids, prior to enrollment, or with immunomodulators or immunosuppressant drugs, including but not limited to inter leukin (il)-6 inhibitors, tumor necrosis factor (tnf) inhibitors, anti-il-1 agents and janus kinase (jak) inhibitors within 5 half-lives or 30 days (whichever is longer) prior to randomization. 5. currently receiving immunosuppressants, including steroids, prior to enrollment 6. serious underlying disease including but not limited to cardiac, pulmonary, renal, hepatic (bilirubin >1.5x upper normal limit (uln) or aspartate aminotransferase (ast)>uln but bilirubin ≤ uln), endocrine (diabetes) or psychiatric disorders judged to be at risk in participating by the inpatient attending physician or team 7. suspected or confirmed history of alcohol or substance abuse disorder 8. having participated in other drug trials in the past month 9. deemed otherwise unsuitable for the study by researchers 10. clinically judged to not require hospital admission

1. known or suspected allergy to rapa 2. high pro-calcitonin 3. sars-cov2 documented by negative rt-pcr nasopharyngeal swab 4. treatment with contraindicated concomitant medications: currently receiving immunosuppressants, including steroids, prior to enrollment, or with immunomodulators or immunosuppressant drugs, including but not limited to inter leukin (il)-6 inhibitors, tumor necrosis factor (tnf) inhibitors, anti-il-1 agents and janus kinase (jak) inhibitors within 5 half-lives or 30 days (whichever is longer) prior to randomization. 5. currently receiving immunosuppressants, including steroids, prior to enrollment 6. serious underlying disease including but not limited to cardiac, pulmonary, renal, hepatic (bilirubin >1.5x upper normal limit (uln) or aspartate aminotransferase (ast)>uln but bilirubin ≤ uln), endocrine (diabetes) or psychiatric disorders judged to be at risk in participating by the inpatient attending physician or team 7. suspected or confirmed history of alcohol or substance abuse disorder 8. having participated in other drug trials in the past month 9. deemed otherwise unsuitable for the study by researchers 10. clinically judged to not require hospital admission